Pharsight

Drugs that contain Drospirenone; Ethinyl Estradiol; Levomefolate Calcium

1. Beyaz patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
USRE43916 BAYER HLTHCARE Composition for contraception
Jun, 2014

(9 years ago)

USRE37838 BAYER HLTHCARE Composition for contraception
Jun, 2014

(9 years ago)

USRE37564 BAYER HLTHCARE Composition for contraception
Jun, 2014

(9 years ago)

USRE38253 BAYER HLTHCARE Composition for contraception
Jun, 2014

(9 years ago)

US5798338 BAYER HLTHCARE Solid dosage forms that contain clathrates of 17α-ethinyl estradiol
Jul, 2015

(8 years ago)

US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Apr, 2020

(4 years ago)

US6958326 BAYER HLTHCARE Cyclodextrin-drospirenone inclusion complexes
Dec, 2021

(2 years ago)

US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(2 years ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(5 years from now)

US11617751 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Sep 24, 2013
New Combination(NC) Sep 24, 2013

Market Authorisation Date: 24 September, 2010

Treatment: Method of inducing contraception in a female of reproductive age who has not yet reached premenopause; Prevention of pregnancy; Treatment of mood changes and/or anxiety as symptoms of premenstrual dys...

Dosage: TABLET;ORAL

How can I launch a generic of BEYAZ before it's drug patent expiration?
More Information on Dosage

BEYAZ family patents

Family Patents

2. Safyral patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5798338 BAYER HLTHCARE Solid dosage forms that contain clathrates of 17α-ethinyl estradiol
Jul, 2015

(8 years ago)

US6441168 BAYER HLTHCARE Stable crystalline salts of 5-methyltetrahydrofolic acid
Apr, 2020

(4 years ago)

US6958326 BAYER HLTHCARE Cyclodextrin-drospirenone inclusion complexes
Dec, 2021

(2 years ago)

US7163931 BAYER HLTHCARE Compositions of estrogen-cyclodextrin complexes
Mar, 2022

(2 years ago)

US8617597 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Feb, 2030

(5 years from now)

US11617751 BAYER HLTHCARE Pharmaceutical composition containing a tetrahydrofolic acid
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 16, 2013

Market Authorisation Date: 16 December, 2010

Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...

Dosage: TABLET;ORAL

How can I launch a generic of SAFYRAL before it's drug patent expiration?
More Information on Dosage

SAFYRAL family patents

Family Patents